| 1 |
34136913 | Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis. | 2022 Jan 11 |
2 |
| 2 |
34189716 | Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors. | 2022 Jan |
2 |
| 3 |
34370645 | Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review. | 2022 |
4 |
| 4 |
34381005 | Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. | 2022 Apr 1 |
2 |
| 5 |
34464920 | Multi-Spectroscopic, thermodynamic and molecular dynamic simulation studies for investigation of interaction of dapagliflozin with bovine serum albumin. | 2022 Jan 5 |
1 |
| 6 |
34507895 | The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis. | 2022 Apr |
1 |
| 7 |
34516288 | Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure. | 2022 Jan 6 |
2 |
| 8 |
34545979 | Renoprotection with sodium-glucose cotransporter-2 inhibitors in children: Knowns and unknowns. | 2022 Feb |
1 |
| 9 |
34610204 | Effectiveness and safety of ertugliflozin for type 2 diabetes: A meta-analysis of data from randomized controlled trials. | 2022 Mar |
1 |
| 10 |
34696609 | Patients With SGLT2 Inhibitor Therapy Can Reliably Measure Their Blood Glucose Without Interference Issues When Up-to-Date Potentiometric and Amperometric Blood Glucose Measurement Systems Are Used. | 2022 Jan |
1 |
| 11 |
34713897 | Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease. | 2022 Feb |
4 |
| 12 |
34716213 | Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial. | 2022 Feb 1 |
3 |
| 13 |
34728212 | Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels? | 2022 Feb |
2 |
| 14 |
34748021 | Association Between SGLT2 Inhibitors vs DPP-4 Inhibitors and Risk of Pneumonia Among Patients With Type 2 Diabetes. | 2022 Mar 24 |
2 |
| 15 |
34750713 | The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. | 2022 Jun |
1 |
| 16 |
34755315 | Healthcare disparities in heart failure patients (with and without type 2 diabetes) and use of sodium glucose co-transport inhibitors (SGLT2-i). | 2022 Feb |
1 |
| 17 |
34784839 | Cardiovascular benefit of SGLT2 inhibitors. | 2022 May |
4 |
| 18 |
34843980 | Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy. | 2022 Feb |
2 |
| 19 |
34860594 | Treatments for skeletal muscle abnormalities in heart failure: sodium-glucose transporter 2 and ketone bodies. | 2022 Feb 1 |
4 |
| 20 |
34865099 | Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice. | 2022 Apr 25 |
1 |
| 21 |
34880492 | Structure and mechanism of the SGLT family of glucose transporters. | 2022 Jan |
1 |
| 22 |
34880493 | Structural basis of inhibition of the human SGLT2-MAP17 glucose transporter. | 2022 Jan |
5 |
| 23 |
34896968 | Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+]c/ROS-pathway in human endothelial cells. | 2022 Feb |
1 |
| 24 |
34898883 | Insulin and glucose infusion could prevent euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter 2 inhibitors. | 2022 Jan |
1 |
| 25 |
34908510 | Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. | 2022 Jan |
2 |
| 26 |
34910981 | Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers. | 2022 Mar |
1 |
| 27 |
34923429 | Exploring sodium glucose cotransporter (SGLT2) inhibitors with machine learning approach: A novel hope in anti-diabetes drug discovery. | 2022 Mar |
1 |
| 28 |
34939679 | Three new categories of hypoglycaemic agents and various cardiovascular diseases: A meta-analysis. | 2022 May |
1 |
| 29 |
34953655 | Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials. | 2022 Mar |
1 |
| 30 |
34982348 | Empagliflozin Ameliorates Ouabain-Induced Na+ and Ca2+ Dysregulations in Ventricular Myocytes in an Na+-Dependent Manner. | 2022 Jan 4 |
2 |
| 31 |
35000594 | Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors. | 2022 Jan 10 |
1 |
| 32 |
35013111 | Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells. | 2022 Jan 10 |
1 |
| 33 |
35039597 | Direct evidence of proximal tubular proliferation in early diabetic nephropathy. | 2022 Jan 17 |
1 |
| 34 |
35053290 | Antioxidant Roles of SGLT2 Inhibitors in the Kidney. | 2022 Jan 16 |
2 |
| 35 |
35067495 | Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes. | 2022 Jan 22 |
2 |
| 36 |
35086983 | Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system. | 2022 Mar 1 |
1 |
| 37 |
35088160 | Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD. | 2022 Jan 27 |
2 |
| 38 |
35090150 | Random-walk model of the sodium-glucose transporter SGLT2 with stochastic steps and inhibition. | 2022 Mar 1 |
4 |
| 39 |
35098383 | Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes. | 2022 Jan 31 |
3 |
| 40 |
35100586 | Effect of SGLT2 Inhibitors on Risk of Stroke in Diabetes: A Meta-Analysis. | 2022 Jan 31 |
1 |
| 41 |
35103458 | Predicting the response to SGLT-2 inhibitors as add-on therapy to multiple day injection insulin with glycated albumin: a pilot study. | 2022 Feb 1 |
2 |
| 42 |
35113333 | Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. | 2022 Jan |
1 |
| 43 |
35121148 | Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors? | 2022 Mar |
1 |
| 44 |
35143848 | Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. | 2022 May |
1 |
| 45 |
35145275 | Kidney and heart failure outcomes associated with SGLT2 inhibitor use. | 2022 May |
2 |
| 46 |
35148777 | SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways. | 2022 Feb 11 |
1 |
| 47 |
35155918 | Breath Analysis for the In Vivo Detection of Diabetic Ketoacidosis. | 2022 Feb 8 |
1 |
| 48 |
35198947 | "Greedy Organs Hypothesis" for sugar and salt in the pathophysiology of non-communicable diseases in relation to sodium-glucose co-transporters in the intestines and the kidney. | 2022 Mar |
1 |
| 49 |
35199478 | Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies. | 2022 Feb 24 |
1 |
| 50 |
35203411 | Inhibition of SGLT2 Preserves Function and Promotes Proliferation of Human Islets Cells In Vivo in Diabetic Mice. | 2022 Jan 18 |
2 |